Modality
Cell Therapy
MOA
ALKi
Target
Aβ
Pathway
Tau
T2D
Development Pipeline
Preclinical
~Jan 2023
→ ~Apr 2024
Phase 1
Jul 2024
→ Aug 2031
Phase 1Current
NCT07323038
1,107 pts·T2D
2024-07→2031-08·Completed
1,107 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-08-145.4y awayInterim· T2D
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
Catalysts
Interim
2031-08-14 · 5.4y away
T2D
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07323038 | Phase 1 | T2D | Completed | 1107 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 |